Bayer’s Kidney Disease Drug Disappoints On Cutting Cardiovascular Death
Bayer AG (OTC:BAYRY) reported disappointing results from its approved med Kerendia (finerenone) didn’t reach significance on all-cause mortality in a pooled…
Bayer, Exscientia Part Ways On Artificial Intelligence Collaboration
Exscientia Plc (NASDAQ:EXAI) has ended its collaboration with Bayer AG (OTC: BAYRY) following the achievement of a drug discovery milestone. Exscientia will retain the…
Science Wednesday: ‘Silent Spring’ At 60; Preserved Baby Mammoth Found In Yukon; Filling Medical Imaging, Nursing Shortages
(This marks the first installment of Benzinga’s new weekly series Science Wednesday, which provides an overview of news and milestones within the sciences.)
Read Why Did HC Wainwright Cut Price Target On Atara Biotherapeutics
Late last week, Atara Biotherapeutics Inc (NASDAQ:ATRA) announced that Bayer AG (OTC:BAYRY) intends to terminate the exclusive worldwide licensing agreement for Atara’s mesothelin-targeted allogeneic…
The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn’s Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Here's a roundup of top developments in the biotech space over the last 24 hours:
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
Atara Biotherapeutics Inc (NASDAQ:ATRA) received notification that Bayer AG’s (OTC:BAYRY) intends to end the exclusive worldwide licensing agreement for mesothelin-directed CAR T-cell therapies.…
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.
Recap: Bayer Q4 Earnings
Bayer (OTC:BAYRY) reported its Q4 earnings results on Tuesday, March 1, 2022 at 01:30 AM.
Here's what investors need to know about the announcement.
Earnings
Bayer beat estimated earnings by 33.33%, reporting an EPS of $0.36 versus an estimate of $0.27.
Aveo Says Tivozanib Patients Up To 5X More Likely To Experience Long-Term PFS Vs. Nexavar In Kidney Cancer
Aveo Pharmaceuticals Inc (NASDAQ: AVEO) will present
